CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

If you're focused on delivering a high return on capital for your shareholders, you should consider M&A as an integral part ...

India’s pharmaceutical sector is at a pivotal moment, with active pharmaceutical ingredients (APIs) presenting a ...

McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the ...

The 5th meeting of the Higher Committee commenced with the attendance of Industry Ministers from seven countries ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...

The pharmaceutical industry is bracing for potentially major disruptions following US President Donald Trump’s announcement ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses ...